This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints
by Zacks Equity Research
Immunovant slips 2.4% after batoclimab misses key phase III endpoints in thyroid eye disease trials, despite stable safety and signs of biological activity.
CPRXPositive Net Change ANIPPositive Net Change IMVTPositive Net Change INDVNegative Net Change
biotechs
RARE Rises as FDA Accepts Resubmitted BLA for Sanfilippo Syndrome
by Zacks Equity Research
Ultragenyx Pharmaceutical jumps 5% as the FDA accepts UX111 BLA resubmission, setting up a September 2026 decision for a potential first treatment for MPS IIIA.
CPRXPositive Net Change ANIPPositive Net Change RAREPositive Net Change INDVNegative Net Change
biotechs
How Will Skyrizi and Rinvoq Shape AbbVie's Q1 Immunology Sales?
by Sundeep Ganoria
ABBV heads into Q1 earnings with Skyrizi and Rinvoq in focus as Humira declines, while growth from new indications and market share gains is under watch.
JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs earnings medical pharmaceuticals
Janux Therapeutics Secures $35M Milestone Payment From BMY Deal
by Zacks Equity Research
JANX earns $35M milestone payment from Bristol Myers as TRACTr-based cancer candidate advances, signaling progress in its tumor-activated therapy platform.
ANIPPositive Net Change ADMAPositive Net Change JANXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bayer Advances AB-1002 Study, Highlights Pharma Growth Strategy
by Zacks Equity Research
Bayer advances AB-1002 after AskBio completes mid-stage study enrollment, as its Pharma strategy and pipeline milestones drive long-term growth outlook.
REGNNegative Net Change JNJNegative Net Change BAYRYPositive Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study
by Zacks Equity Research
Ocugen completes GARDian3 enrollment early as OCU410ST gene therapy targets Stargardt disease with no approved treatments. Data readouts are expected in Q3.
CPRXPositive Net Change ANIPPositive Net Change OCGNNegative Net Change INDVNegative Net Change
biotechs
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
by Kinjel Shah
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.
INDVNegative Net Change CPRXPositive Net Change TBPHPositive Net Change RLMDNegative Net Change AVTXNegative Net Change
biotechs pharmaceuticals
LLY Stock Up on GLP-1 Pill Approval: Can it Outpace NVO's Wegovy Pill?
by Ahan Chakraborty
Eli Lilly stock gains on FDA nod for oral obesity drug Foundayo, expanding its portfolio and patient access, setting up a fresh showdown with Novo Nordisk in the GLP-1 market.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD posts wider Q4 loss. However, its pipeline advances, with strong phase III data for Zenkuda driving accelerated regulatory plans.
CPRXPositive Net Change ANIPPositive Net Change KODNegative Net Change INDVNegative Net Change
biotechs
SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug
by Zacks Equity Research
Scholar Rock stock jumps 14% after it resubmits its FDA filing for SMA drug apitegromab, revives approval hopes and sets up a potential September 2026 decision.
NVSNegative Net Change BIIBNegative Net Change RHHBYPositive Net Change SRRKNegative Net Change
biotechs medical pharmaceuticals